CMS Manual System	Department of Health & Human Services (DHHS)
Pub 100-04 Medicare Claims Processing	Centers for Medicare & Medicaid Services (CMS)
Transmittal 11849	Date: February 9, 2023
	Change Request 13089

SUBJECT: April 2023 Quarterly Update to HCPCS Codes Used for Skilled Nursing Facility (SNF) Consolidated Billing (CB) Enforcement

I. SUMMARY OF CHANGES: The purpose of this CR is to provide updates to the lists of HCPCS codes that are subject to the consolidated billing provision of the SNF Prospective Payment System (PPS).

Changes to Current Procedural Terminology/Healthcare Common Procedure Coding System (CPT/HCPCS) codes and Medicare Physician Fee Schedule designations will be used to revise CWF edits to allow MACs to make appropriate payments in accordance with policy for SNF consolidated billing in chapter 6, section 20.6.

EFFECTIVE DATE: April 1, 2023

*Unless otherwise specified, the effective date is the date of service. IMPLEMENTATION DATE: April 3, 2023

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated) R=REVISED, N=NEW, D=DELETED-*Only One Per Row.*

R/N/D	CHAPTER / SECTION / SUBSECTION / TITLE
N/A	N/A

III. FUNDING:

For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

IV. ATTACHMENTS:

Recurring Update Notification

Attachment - Recurring Update Notification

Pub. 100-04	Transmittal: 11849	Date: February 9, 2023	Change Request: 13089
-------------	--------------------	------------------------	-----------------------

SUBJECT: April 2023 Quarterly Update to HCPCS Codes Used for Skilled Nursing Facility (SNF) Consolidated Billing (CB) Enforcement

EFFECTIVE DATE: April 1, 2023 *Unless otherwise specified, the effective date is the date of service. **IMPLEMENTATION DATE: April 3, 2023**

I. GENERAL INFORMATION

A. Background: The Centers for Medicare & Medicaid Services (CMS) periodically updates the lists of Healthcare Common Procedure Coding System (HCPCS) codes that are **excluded** from the CB provision of the SNF Prospective Payment System (PPS). Services **excluded** from SNF PPS and CB may be paid to providers, other than SNFs, for beneficiaries, even when in a SNF stay. Services not appearing on the **exclusion** lists submitted on claims to Medicare Administrative Contractors (MACs), including Durable Medical Equipment MACs (DME MACs), will not be paid by Medicare to any providers other than a SNF. For non-therapy services, SNF CB applies only when the services are furnished to a SNF resident during a covered Part A stay; however, SNF CB applies to physical and occupational therapies and speech-language pathology services whenever they are furnished to a SNF resident, regardless of whether Part A covers the stay. In order to assure proper payment in all settings, Medicare systems must edit for services provided to SNF beneficiaries both included and excluded from SNF CB.

The updated lists for institutional and professional billing are available at: http://www.cms.gov/Medicare/Billing/SNFConsolidatedBilling/

This quarterly update includes revisions to the Part B SNF CB files for 2018 - 2023, which in part, attempts to reconcile the Part A SNF CB file and the Part B SNF CB files, includes revisions due to policy determinations, and codes that may have been erroneously omitted from the files. The changes are as follows:

File 1 Revisions - Additions

Addition of Coronavirus Disease 2019 (COVID-19) vaccines and appropriate administration codes to File 1 for 2023. The following codes were effective December 8, 2022 and implemented via technical direction:

91316

91317

0164A

0173A

The following codes for blood clotting factors were effective October 1, 2021 and implemented with October 2021 quarterly update. The codes were not added to the Part B SNF CB files for 2022 and 2023. The following HCPCS codes shall be added to the Part B SNF CB File #1 for 2022 and 2023:

J7170 INJ., EMICIZUMAB-KXWH 0.5 MG J7175 INJ, FACTOR X, (HUMAN), 1IU J7179 VONVENDI INJ 1 IU VWF:RCO J7180 FACTOR XIII ANTI-HEM FACTOR J7181 FACTOR XIII RECOMB A-SUBUNIT J7182 FACTOR VIII RECOMB NOVOEIGHT J7183 WILATE INJECTION J7185 XYNTHA INJ J7186 ANTIHEMOPHILIC VIII/VWF COMP J7187 HUMATE-P, INJ J7188 FACTOR VIII RECOMB OBIZUR J7189 FACTOR VIIA RECOMB NOVOSEVEN J7190 FACTOR VIII J7191 FACTOR VIII (PORCINE) J7192 FACTOR VIII RECOMBINANT NOS J7193 FACTOR IX NON-RECOMBINANT J7194 FACTOR IX COMPLEX J7195 FACTOR IX RECOMBINANT NOS J7196 ANTITHROMBIN RECOMBINANT J7197 ANTITHROMBIN III INJECTION J7198 ANTI-INHIBITOR J7199 HEMOPHILIA CLOT FACTOR NOC J7200 FACTOR IX RECOMBINAN RIXUBIS J7201 FACTOR IX ALPROLIX RECOMB J7202 FACTOR IX IDELVION INJ J7203 FACTOR IX RECOMB GLY REBINYN J7204 INJ., FACTOR VIII, ANTIHEMOPHILIC FACTOR (RECOMBINANT), (ESPEROCT), GLYCOPEGYLATED-EXEI, J7205 FACTOR VIII FC FUSION RECOMB J7207 FACTOR VIII PEGYLATED RECOMB J7209 FACTOR VIII NUWIQ RECOMB 1IU J7210 INJ, AFSTYLA, 1 I.U. J7211 INJ, KOVALTRY, 1 I.U. J7212 FACTOR VIIA RECOMB SEVENFACT

J7204 INJ., FACTOR VIII, ANTIHEMOPHILIC FACTOR (RECOMBINANT), (ESPEROCT), GLYCOPEGYLATED-EXEI

The following codes for blood clotting factors were effective July 1, 2021 and implemented with October 2021 quarterly update. The code was not added to the Part B SNF CB files for 2022 and 2023. The following HCPCS code shall be added to the Part B SNF CB File #1 for 2021 - 2023:

Q5123 INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG

The following HCPCS codes were effective January 9, 2023. The following HCPCS codes shall be added to the Part B SNF File #1 for 2023:

J0892 ARGATROBAN DIALYSIS (ACCORD)

J0899 ARGATROBAN DIALYSIS, AUROMED

The following HCPCS codes were effective January 1, 2023. The HCPCS codes shall be added to processing File #1 for 2023

M1187 PT W/ ESRD

J0893 INJ, DECITABINE (SUN PHARMA)

J9046 INJ, BORTEZOMIB, DR. REDDY'S

J9048 INJ, BORTEZOMIB FRESENIUSKAB

J9049 INJ, BORTEZOMIB, HOSPIRA

J9393 INJ, FULVESTRANT (TEVA)

J9394 INJ, FULVESTRANT (FRESENIUS)

Q5126 INJ ALYMSYS 10 MG

J0893 INJ, DECITABINE (SUN PHARMA)

J0891 ARGATROBAN NONESRD (ACCORD)

J0898 ARGATROBAN NONESRD (AUROMED)

The following HCPCS code became effective April 1, 2022. The HCPCS code shall be added to processing File #1 for 2022:

J0879 INJECTION, DIFELIKEFALIN, 0.1 MICROGRAM, (FOR ESRD ON DIALYSIS)

The following HCPCS code became effective July 1, 2019. The HCPCS code shall be added to processing File #1 for 2019 - 2023:

J1444 FE PYRO CIT POW 0.1 MG IRON

File 1 - DELETIONS

The following HCPCS codes shall be removed from File #1 effective January 1, 2023

C9142 INJ, ALYMSYS, 10 MG

J9044 INJ, BORTEZOMIB, NOS, 0.1 MG

The Part A file updates are:

ADD EFFECTIVE DATE IS January 1, 2023, UNLESS OTHERISE NOTED

Major Category III. A. -Chemotherapy

J0893 INJ, DECITABINE (SUN PHARMA)

J9046 INJ, BORTEZOMIB, DR. REDDY'S

J9048 INJ, BORTEZOMIB FRESENIUSKAB

J9049 INJ, BORTEZOMIB, HOSPIRA

J9393 INJ, FULVESTRANT (TEVA)

J9394 INJ, FULVESTRANT (FRESENIUS)

Q5126 INJ ALYMSYS 10 MG

Major Category III. E. - E. Certain blood clotting factors indicated for the treatment of hemophilia and other bleeding disorders

J0891 ARGATROBAN NONESRD (ACCORD)

J0898 ARGATROBAN NONESRD (AUROMED)

Major Category IV. B. - Vaccines (Pneumococcal, Flu, Hepatitis B, or Covid-19)

91307 SARSCOV2 VAC 10 MCG TRS-SUCR Effective October 29, 2021

91308 SARSCOV2 VAC 3MCG TRS-SUCR Effective June 17, 2022

91309 SARSCOV2 VAC 50MCG/0.5ML IM Effective March 29, 2022

91316 SARSCOV2 VAC BVL 10MCG/0.2ML Effective: December 8, 2022

91317 SARSCOV2 VAC BVL 3MCG/0.2ML Effective : December 8, 2022

Major Category IV. C. - Vaccine Administration

0034A ADM SARSCOV2 VAC AD26 .5ML B Effective: October 20,2021

0044A ADM SARSCOV2 5MCG/0.5ML BST Effective: October 19, 2021

0071A ADM SARSCV2 10MCG TRS-SUCR 1 Effective: October 29, 2021

0072A ADM SARSCV2 10MCG TRS-SUCR 2 Effective: October 29, 2021

0073A ADM SARSCV2 10MCG TRS-SUCR 3 Effective: January 3, 2022

0074A ADM SARSCV2 10MCG TRS-SUCR B Effective: May 17, 2022

0081A ADM SARSCOV2 3MCG TRS-SUCR 1 Effective: June 17, 2022

0082A ADM SARSCOV2 3MCG TRS-SUCR 1 Effective: June 17, 2022

0083A ADM SARSCOV2 3MCG TRS-SUCR 2 Effective: June 17, 2022

0094A ADM SARSCOV2 50MCG/0.5 MLBST Effective: March 29, 2022

0164A ADM SRSCV2 BVL 10MCG/0.2ML B Effective: December 8, 2022

0173A ADM SARSCV2 BVL 3MCG/0.2ML 3 Effective: December 8, 2022

DELETE TEMINATION DATE January 1, 2023

Major Category III. A. -Chemotherapy

C9142 INJ, ALYMSYS, 10 MG

J9044 INJ, BORTEZOMIB, NOS, 0.1 MG

B. Policy: Section 1888 of the Social Security Act codifies SNF PPS and CB. The new coding identified in each update describes the same services that are subject to SNF PPS payment by law. No additional services will be added by these routine updates; that is, new updates are required by changes to the coding system, not because the services subject to SNF CB are being redefined. Other regulatory changes beyond code list updates will be noted when and if they occur.

II. BUSINESS REQUIREMENTS TABLE

"Shall" denotes a mandatory requirement, and "should" denotes an optional requirement.

Number	Requirement	Re	espo	nsil	bilit	y						
				MAC 1				DShared-MSystemEMaintainers			L	Other
		A	В	H H H	M A C	F I S S	M C S					
13089.1	The Common Working File (CWF) shall add the following HCPCS code to File '1' for years 2020 – 2023. The effective date is July 1, 2020 per technical direction: Q5119 Inj ruxience, 10 mg								X			
13089.2	CWF shall add the following HCPCS codes to File #1 for 2022 and 2023. The effective date is December 8, 2022 per technical direction:								X			
	91316 SARSCOV2 VAC BVL 10MCG/0.2ML 91317 SARSCOV2 VAC BVL 3MCG/0.2ML 0164A ADM SRSCV2 BVL 10MCG/0.2ML B											

Number	Requirement	R	espo	nsil	bilit	y				
			A/B		D		Sha			Other
		N	ЛАC	~	M E		Sys aint			
		Α	В	H	М	F	M			
				H H	M A		C S	M S	W F	
	0173A ADM SARSCV2 BVL 3MCG/0.2ML 3				С	S				
13089.3	CWF shall add the following HCPCS code to File #1 for 2021 – 2023. The effective date is July 1, 2021 per technical direction:								Х	
	Q5123 INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG									
13089.4	CWF shall add the following HCPCS codes to the 2022 and 2023 processing File #1 – retroactive to								Х	
	October 1, 2021 per technical direction:									
	J7170 INJ., EMICIZUMAB-KXWH 0.5 MG									
	J7175 INJ, FACTOR X, (HUMAN), 1IU									
	J7179 VONVENDI INJ 1 IU VWF:RCO									
	J7180 FACTOR XIII ANTI-HEM FACTOR									
	J7170 INJ., EMICIZUMAB-KXWH 0.5 MG									
	J7175 INJ, FACTOR X, (HUMAN), 1IU									
	J7179 VONVENDI INJ 1 IU VWF:RCO									
	J7180 FACTOR XIII ANTI-HEM FACTOR									
	J7181 FACTOR XIII RECOMB A-SUBUNIT									
	J7182 FACTOR VIII RECOMB NOVOEIGHT									
	J7183 WILATE INJECTION									
	J7185 XYNTHA INJ									
	J7186 ANTIHEMOPHILIC VIII/VWF COMP									
	J7187 HUMATE-P, INJ									

Number	Requirement	Re	espo	nsil	bilit	у				
			A/B		D			red-		Other
		N	ЛАC		M E		•	tem aine		
		А	В	Н		F	М	V	С	
				H H	M A	I S	C S	M S	W F	
					С	S				
	J7188 FACTOR VIII RECOMB OBIZUR									
	J7189 FACTOR VIIA RECOMB NOVOSEVEN									
13089.5	CWF shall add the following HCPCS codes to the 2021-2023 processing File #1 – retroactive to October 1, 2021 per technical direction:								Х	
	J7190 FACTOR VIII									
	J7191 FACTOR VIII (PORCINE)									
	J7192 FACTOR VIII RECOMBINANT NOS									
	J7193 FACTOR IX NON-RECOMBINANT									
	J7194 FACTOR IX COMPLEX									
	J7195 FACTOR IX RECOMBINANT NOS									
	J7196 ANTITHROMBIN RECOMBINANT									
	J7197 ANTITHROMBIN III INJECTION									
	J7198 ANTI-INHIBITOR									
	J7199 HEMOPHILIA CLOT FACTOR NOC									
	J7200 FACTOR IX RECOMBINAN RIXUBIS									
	J7201 FACTOR IX ALPROLIX RECOMB									
	J7202 FACTOR IX IDELVION INJ									
	J7203 FACTOR IX RECOMB GLY REBINYN									
	J7205 FACTOR VIII FC FUSION RECOMB									
	J7207 FACTOR VIII PEGYLATED RECOMB									
	J7209 FACTOR VIII NUWIQ RECOMB 1IU									
	J7210 INJ, AFSTYLA, 1 I.U.									

Number	Requirement	Re	espo	onsil	bilit					
			A/B MA(D M E		Sys	red- tem aine		Other
		А	В	H H H		F I	M	1	С	
13089.6	J7211 INJ, KOVALTRY, 1 I.U. J7212 FACTOR VIIA RECOMB SEVENFACT J7204 INJ.,FACTOR VIII, ANTIHEMOPHILIC FACTOR (RECOMBINANT), (ESPEROCT), GLYCOPEGYLATED-EXEI								X	
	2023 processing File #1 retroactive to January 9, 2023 per technical direction: J0892 ARGATROBAN DIALYSIS (ACCORD) J0899 ARGATROBAN DIALYSIS, AUROMED									
13089.7	CWF shall add the following HCPCS codes to File #1. The effective date is January 1, 2023: M1187 PT W/ ESRD J0893 INJ, DECITABINE (SUN PHARMA) J9046 INJ, BORTEZOMIB, DR. REDDY'S J9048 INJ, BORTEZOMIB FRESENIUSKAB J9049 INJ, BORTEZOMIB, HOSPIRA J9393 INJ, FULVESTRANT (TEVA) J9394 INJ, FULVESTRANT (FRESENIUS) Q5126 INJ ALYMSYS 10 MG J0893 INJ, DECITABINE (SUN PHARMA) J0891 ARGATROBAN NONESRD (ACCORD)								X	

Number	Requirement	Re	espo	nsil	bilit	y				
			A/B		D		Sha	red-		Other
		N	MAG		Μ		•	tem		
					Е	Μ	aint	aine	ers	
		Α	В	Η		F	Μ			
				Η	M	-	С	Μ		
				Η	A C		S	S	F	
13089.8	CWF shall add the following HCPCS code to File #1				C	S			Х	
13089.8	for 2022. The effective date is April 1, 2022:								Λ	
	J0879 INJECTION, DIFELIKEFALIN, 0.1									
	MICROGRAM, (FOR ESRD ON DIALYSIS)									
	MICROORANN, (I OR ESKD ON DIAL I SIS)									
13089.9	CWF shall add the following HCPCS code to File #1								Х	
	for 2019-2023. The effective date is July 1, 2019:									
	J1444 FE PYRO CIT POW 0.1 MG IRON									
13089.10	CWF shall remove the following HCPCS from								Х	
15005.10	processing File #1 effective January 1, 2023:								11	
	· · · · · · · · · · · · · · · · · · ·									
	C9142 INJ, ALYMSYS, 10 MG									
	10044 INL DODTEZOMID NOS 0.1 MC									
	J9044 INJ, BORTEZOMIB, NOS, 0.1 MG									
13089.11	CWF shall add the following HCPCS codes to the Part								Х	
	A File. The effective date is December 8, 2022 per									
	technical direction:									
	Maior Catagory IV B. Vassing (Provense)									
	Major Category IV. B Vaccines (Pneumococcal, Flu, Hepatitis B, or Covid-19)									
	,puttion 27, or (7)									
	91316 SARSCOV2 VAC BVL 10MCG/0.2ML									
	91317 SARSCOV2 VAC BVL 3MCG/0.2ML									
	Major Category IV. C Vaccine Administration									
	0164A ADM SRSCV2 BVL 10MCG/0.2ML B									
	0173A ADM SARSCV2 BVL 3MCG/0.2ML 3									
13089.12	CWF shall add the following HCPCS codes to the Part								Х	
	A File. The effective date is October 29, 2021 per									
	technical direction:									
	Major Category IV. B Vaccines (Pneumococcal, Flu, Hepatitis B, or Covid-19)									
	The meranus D, or Covid-19)									

Number	Requirement	Re	espo	nsil	bilit	y							
			A/B		D			red-		Other			
		MAC		M		Sys							
		Α	В	Н	E	F	aint M	aine V	$\frac{\text{ers}}{\text{C}}$				
		A	D	пН	Μ		C	v M					
				Н	А	S	S	S	F				
					С	S							
	91307 SARSCOV2 VAC 10 MCG TRS-SUCR												
	Major Category IV. C Vaccine Administration												
	0071A ADM SARSCV2 10MCG TRS-SUCR 1												
	0072A ADM SARSCV2 10MCG TRS-SUCR 2												
13089.13	CWF shall add the following HCPCS codes to the Part A File. The effective date is March 29, 2022 per technical direction:								Х				
	Major Category IV. B Vaccines (Pneumococcal, Flu, Hepatitis B, or Covid-19)												
	91309 SARSCOV2 VAC 50MCG/0.5ML IM												
	Major Category IV. C Vaccine Administration												
	0094A ADM SARSCOV2 50MCG/0.5 MLBST												
13089.14	CWF shall add the following HCPCS codes to the Part A File. The effective date is June 17, 2022 per technical direction:								Х				
	Major Category IV. B Vaccines (Pneumococcal, Flu, Hepatitis B, or Covid-19)												
	91308 SARSCOV2 VAC 3MCG TRS-SUCR												
	Major Category IV. C Vaccine Administration												
	0081A ADM SARSCOV2 3MCG TRS-SUCR 1												
	0082A ADM SARSCOV2 3MCG TRS-SUCR 1												
	0083A ADM SARSCOV2 3MCG TRS-SUCR 2												
13089.15	CWF shall add the following HCPCS codes to the Part A File. The effective date is October 20, 2021 per technical direction:								X				
	Major Category IV. C Vaccine Administration												

Number	Requirement	Re	espo	nsil	bilit							
			A/B		D		Sha			Other		
		MAC			MAC		M E		Sys aint			
		A	В	Н	Ľ	F	M					
				Η	M	Ι	С	Μ	W			
				Η	A C	S S	S	S	F			
	0034A ADM SARSCOV2 VAC AD26 .5ML B											
13089.16	CWF shall add the following HCPCS codes to the Part A File. The effective date is October 19, 2021 per technical direction:								Х			
	Major Category IV. C Vaccine Administration											
	0044A ADM SARSCOV2 5MCG/0.5ML BST											
13089.17	CWF shall add the following HCPCS codes to the Part A File. The effective date is January 3, 2022 per technical direction:								Х			
	Major Category IV. C Vaccine Administration											
	0073A ADM SARSCV2 10MCG TRS-SUCR 3											
13089.18	CWF shall add the following HCPCS codes to the Part A File. The effective date is May 17, 2022 per technical direction:								Х			
	Major Category IV. C Vaccine Administration											
	0074A ADM SARSCV2 10MCG TRS-SUCR B											
13089.19	CWF shall add the following HCPCS codes to the Part A File. The effective date is January 9, 2023 per technical direction:								Х			
	Major Category III. E E. Certain blood clotting factors indicated for the treatment of hemophilia and other bleeding disorders											
	J0891 ARGATROBAN NONESRD (ACCORD)											
	J0898 ARGATROBAN NONESRD (AUROMED)											
13089.20	CWF shall add the following HCPCS codes to the Part A File. The effective date is January 1, 2023:								Х			
	Major Category III. AChemotherapy											

Number	Requirement	Re	espo	nsi	bilit	y																				
			А/В ЛА(D M			red- tem		Other																
																		MAC					•	aine		
		A	В	H H	М	F	M	V M	C W																	
				п Н	А	I S	S S	S	vv F																	
					С	S																				
	J0893 INJ, DECITABINE (SUN PHARMA)																									
	J9046 INJ, BORTEZOMIB, DR. REDDY'S																									
	J9048 INJ, BORTEZOMIB FRESENIUSKAB																									
	J9049 INJ, BORTEZOMIB, HOSPIRA																									
	J9393 INJ, FULVESTRANT (TEVA)																									
	J9394 INJ, FULVESTRANT (FRESENIUS)																									
	Q5126 INJ ALYMSYS 10 MG																									
13089.21	CWF shall remove the following HCPCS from The Part A File effective January 1, 2023:								Х																	
	Major Category III. AChemotherapy																									
	C9142 INJ, ALYMSYS, 10 MG																									
	J9044 INJ, BORTEZOMIB, NOS, 0.1 MG																									
13089.22	Contractors shall not search their files for incorrectly paid claims for HCPCS codes listed in business requirements 13089.1 – 13089.22. However, they shall reopen and reprocess claims when brought to their attention.	X	X																							

III. PROVIDER EDUCATION TABLE

Number	Requirement	Re	spo	nsib	ility	
			A/B MAC		D M	C E
		1	VIIIC	_	E	D
		Α	В	H H	М	Ι
				Н	A C	
13089.23	Medicare Learning Network® (MLN): CMS will market provider education	Χ	Χ			

Number	Requirement	Re	Responsibility			
			A/B MAC B		D M E M A	C E D I
	content through the MLN Connects® newsletter shortly after CMS releases the CR. MACs shall follow IOM Pub. No. 100-09 Chapter 6, Section 50.2.4.1 instructions for distributing the MLN Connects newsletter information to providers and link to relevant information on your website. You may supplement MLN content with your local information after we release the MLN Connects newsletter. Subscribe to the "MLN Connects" listserv to get MLN content notifications. You don't need to separately track and report MLN content releases when you distribute MLN Connects newsletter content per the manual section referenced above.				С	

IV. SUPPORTING INFORMATION

Section A: Recommendations and supporting information associated with listed requirements: N/A

"Should" denotes a recommendation.

X-Ref	Recommendations or other supporting information:
Requirement	
Number	

Section B: All other recommendations and supporting information: N/A

V. CONTACTS

Pre-Implementation Contact(s): Bridgitte Davis-Hawkins, bridgitte.davis-hawkins@cms.hhs.gov (Part B Claims), Valeri Ritter, 410-786-8652 or valeri.ritter@cms.hhs.gov (Part A Claims)

Post-Implementation Contact(s): Contact your Contracting Officer's Representative (COR).

VI. FUNDING

Section A: For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

ATTACHMENTS: 0